Alliance Global Partners Comments on Tilray Inc’s Q4 2025 Earnings (NASDAQ:TLRY)

Tilray Inc (NASDAQ:TLRY) – Equities researchers at Alliance Global Partners raised their Q4 2025 earnings estimates for shares of Tilray in a note issued to investors on Tuesday, July 30th. Alliance Global Partners analyst A. Grey now anticipates that the company will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.01). Alliance Global Partners currently has a “Neutral” rating and a $2.75 price target on the stock. The consensus estimate for Tilray’s current full-year earnings is ($0.13) per share. Alliance Global Partners also issued estimates for Tilray’s FY2026 earnings at ($0.04) EPS.

Other research analysts also recently issued research reports about the company. Canaccord Genuity Group cut their price target on Tilray from $4.25 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, April 10th. CIBC cut their target price on shares of Tilray from $2.25 to $2.00 and set a “neutral” rating for the company in a research report on Wednesday, April 10th.

Tilray Stock Up 1.0 %

Shares of NASDAQ TLRY opened at $2.03 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.92 and a quick ratio of 1.18. The stock has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $1.90. Tilray has a 1-year low of $1.60 and a 1-year high of $3.40.

Tilray (NASDAQ:TLRY) last released its earnings results on Monday, July 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $229.90 million for the quarter, compared to the consensus estimate of $226.20 million. Tilray had a negative net margin of 30.26% and a negative return on equity of 2.65%. The firm’s revenue was up 24.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.15) earnings per share.

Institutional Trading of Tilray

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James & Associates grew its holdings in Tilray by 20.6% during the 4th quarter. Raymond James & Associates now owns 95,329 shares of the company’s stock valued at $219,000 after buying an additional 16,294 shares in the last quarter. Arizona State Retirement System increased its holdings in Tilray by 8.2% during the 4th quarter. Arizona State Retirement System now owns 204,148 shares of the company’s stock worth $470,000 after acquiring an additional 15,449 shares during the period. International Assets Investment Management LLC lifted its stake in Tilray by 179.0% in the 4th quarter. International Assets Investment Management LLC now owns 14,734 shares of the company’s stock worth $34,000 after purchasing an additional 9,453 shares in the last quarter. Allworth Financial LP boosted its holdings in Tilray by 2,141.1% in the 4th quarter. Allworth Financial LP now owns 80,320 shares of the company’s stock valued at $185,000 after purchasing an additional 76,736 shares during the period. Finally, Stratos Wealth Partners LTD. grew its position in shares of Tilray by 61.1% during the 4th quarter. Stratos Wealth Partners LTD. now owns 165,558 shares of the company’s stock valued at $381,000 after purchasing an additional 62,795 shares in the last quarter. 9.35% of the stock is currently owned by institutional investors.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.